A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Michal SarfatyKarissa A WhitingMin Yuen TeoChung-Han LeeVanessa PetersJennifer DurocherAshley M RegazziAsia S McCoyGrace HettichAchim A JungbluthHikmat A Al-AhmadieIrina OstrovnayaJoshua ChaimDean F BajorinJonathan E RosenbergGopakumar V IyerSamuel A FuntPublished in: Cancer medicine (2020)
In a poor prognosis cohort of patients with non-UC, durvalumab and tremelimumab lacked clinical activity while demonstrating a manageable safety profile.